DK2516468T3 - Anti-flt3-antistoffer og fremgangsmåder til anvendelse af disse - Google Patents
Anti-flt3-antistoffer og fremgangsmåder til anvendelse af disse Download PDFInfo
- Publication number
- DK2516468T3 DK2516468T3 DK10798340.5T DK10798340T DK2516468T3 DK 2516468 T3 DK2516468 T3 DK 2516468T3 DK 10798340 T DK10798340 T DK 10798340T DK 2516468 T3 DK2516468 T3 DK 2516468T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- ser
- antibodies
- thr
- val
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
- ANTI-FLT3-ANTIST0FFER OG FREMGANGSMÅDER TIL ANVENDELSE AF DISSE1. IgG-antistof, der binder human receptortyrosinkinase FLT3, hvilket antistof omfatter en tung kæde og en let kæde og en aminosyresubstitution i den konstante region i forhold til et moder-anti-FLT3-antistof, hvor aminosyresubstitutionen omfatter aminosyresubstitutionerne S239D og I332E, hvor positionsnummereringen er ifølge EU-indekset.
- 2. Antistof ifølge krav 1, hvor Vl-CDR1 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 1; Vl-CDR2 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 2; Vl-CDR3 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 3; Vh-CDR1 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 4; Vh-CDR2 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 5; og VH-CDR3 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 6.
- 3. Antistof ifølge krav 1, hvor Vl-CDR1 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 7; Vl-CDR2 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 8; Vl-CDR3 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 9; Vr-CDRI omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 10; VH-CDR2 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 11; og VH-CDR3 omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 12.
- 4. Antistof ifølge krav 2, hvor den tunge kæde omfatter et Vn-domæne, der omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 14, og den lette kæde omfatter et VL-domæne, der omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 13.
- 5. Antistof ifølge krav 3, hvor den tunge kæde omfatter et VH-domæne, der omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 30, og den lette kæde omfatter et VL-domæne, der omfatter eller består af aminosyresekvensen, der er vist i SEQ ID NO: 29.
- 6. Antistof ifølge krav 1, hvor antistoffet er et kimerisk antistof og omfatter en tung kæde med aminosyresekvensen, der er vist i SEQ ID NO: 27, og en let kæde med aminosyresekvensen, der er vist i SEQ ID NO: 23.
- 7. Antistof ifølge krav 1, hvor antistoffet er et kimerisk antistof og omfatter en tung kæde med amino syre sekvens en, der er vist i SEQ ID NO: 43, og/eller en let kæde med aminosyresekvensen, der er vist i SEQ ID NO: 39.
- 8. Antistof ifølge et hvilket som helst af kravene 1-7, hvor antistoffet binder med forøget affinitet til FcyRIIIa-receptoren eller har forøget ADCC-effektorfunktion sammenlignet med moderantistoffet.
- 9. Nukleinsyremolekyle, der koder for en tung og let kæde af antistoffet ifølge et hvilket som helst af kravene 1-8.
- 10. Antistof ifølge et hvilket som helst af kravene 1-8 til anvendelse i en fremgangsmåde til behandling af et lymfom eller en leukæmi hos et pattedyr.
- 11. Antistof til anvendelse ifølge krav 10, hvor lymfomet eller leukæmien er i stadiet minimal restsygdom (MRD).
- 12. Antistof til anvendelse ifølge krav 10 eller 11, hvor lymfomet eller leukæmien er udvalgt fra gruppen, der består af: non-Hodgkins lymfomer (NHL), kronisk lymfocytisk leukæmi (CLL), B-celle akut lymfoblastær leukæmi/lymfom (B-ALL), mantle celle lymfom (MCL), hårcelleleukæmi (HCL), kronisk myeloid leukæmi (CML), akut myeloid leukæmi (AML) og multipelt myelom (MM).
- 13. Antistof til anvendelse ifølge et hvilket som helst af kravene 10-12, hvor antistoffet administreres i kombination med mindst ét middel, der er udvalgt fra gruppen, der består af et cytotoksisk middel, et kemoterapeutisk middel, et cytokin, et væksthæmmende middel, et antihormonelt middel, en kinasehæmmer, et antiangiogent middel, et hjertebeskyttende middel, et immunstimulatorisk middel, et immunsuppressivt middel, en angiogenesehæmmer, en proteintyrosinkinasehæmmer og et andet antistof.
- 14. Farmaceutisk sammensætning, der omfatter antistoffet ifølge et hvilket som helst af kravene 1-8 og et farmaceutisk acceptabelt bæremateriale.
- 15. Transficeret cellelinje, der danner et antistof ifølge et hvilket som helst af kravene 1-8.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28952909P | 2009-12-23 | 2009-12-23 | |
| PCT/EP2010/070659 WO2011076922A1 (en) | 2009-12-23 | 2010-12-23 | Anti-flt3 antibodies and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2516468T3 true DK2516468T3 (da) | 2016-05-23 |
Family
ID=43719470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10798340.5T DK2516468T3 (da) | 2009-12-23 | 2010-12-23 | Anti-flt3-antistoffer og fremgangsmåder til anvendelse af disse |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9023996B2 (da) |
| EP (1) | EP2516468B1 (da) |
| JP (1) | JP5944831B2 (da) |
| CN (1) | CN102770453B (da) |
| BR (1) | BR112012015740B1 (da) |
| CA (1) | CA2785178C (da) |
| DK (1) | DK2516468T3 (da) |
| EA (1) | EA027502B1 (da) |
| ES (1) | ES2573642T3 (da) |
| HK (1) | HK1172910A1 (da) |
| HR (1) | HRP20160422T1 (da) |
| HU (1) | HUE028629T2 (da) |
| SI (1) | SI2516468T1 (da) |
| WO (1) | WO2011076922A1 (da) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033245T2 (hu) * | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| US10774132B2 (en) * | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
| WO2015001078A1 (en) * | 2013-07-04 | 2015-01-08 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | A new fusion protein to target and treat acute myloid leukemia cells |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| CN104288765A (zh) * | 2014-07-03 | 2015-01-21 | 成都中联生科基因科技有限公司 | 一种利用具有中和FLT3生物学活性的McAb应用于肿瘤的靶向治疗的新方法 |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| CN107250157B (zh) * | 2014-11-21 | 2021-06-29 | 百时美施贵宝公司 | 包含修饰的重链恒定区的抗体 |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| SG11201707195SA (en) * | 2015-03-09 | 2017-10-30 | Agensys Inc | Antibody drug conjugates (adc) that bind to flt3 proteins |
| US20180298068A1 (en) | 2015-04-23 | 2018-10-18 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| KR20180053744A (ko) * | 2015-09-23 | 2018-05-23 | 사이토이뮨 테라퓨틱스 엘엘씨 | 면역 요법을 위한 flt3 유도된 car 세포 |
| SI3380620T1 (sl) | 2015-11-23 | 2024-09-30 | Novartis Ag | Optimizirani lentivirusni prenosni vektorji in njihove uporabe |
| WO2017114497A1 (en) | 2015-12-30 | 2017-07-06 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| IL296966A (en) * | 2016-04-01 | 2022-12-01 | Amgen Inc | Chimeric flt-3 receptors and methods of using them |
| US11021536B2 (en) | 2016-04-04 | 2021-06-01 | Hemogenyx Pharmaceuticals Llc | Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies |
| US11104738B2 (en) | 2016-04-04 | 2021-08-31 | Hemogenyx Pharmaceuticals Llc | Monoclonal antibodies to human FLT3/FLK2 receptor protein |
| WO2017219029A2 (en) | 2016-06-17 | 2017-12-21 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+cells |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| US11236171B2 (en) | 2016-12-21 | 2022-02-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| SG10202102897PA (en) | 2017-01-20 | 2021-04-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
| ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| EP3589647A1 (en) | 2017-02-28 | 2020-01-08 | Novartis AG | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| CN110382529B (zh) * | 2017-03-02 | 2024-03-08 | 诺华股份有限公司 | 工程化的异源二聚体蛋白质 |
| JP7234142B2 (ja) * | 2017-06-02 | 2023-03-07 | ファイザー・インク | Ｆｌｔ３に特異的な抗体およびその使用 |
| CN110831970A (zh) * | 2017-06-02 | 2020-02-21 | 辉瑞公司 | 靶向flt3的嵌合抗原受体 |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| CN111132698A (zh) * | 2017-07-31 | 2020-05-08 | 蜻蜓治疗公司 | 结合nkg2d、cd16以及flt3的蛋白质 |
| CA3071303A1 (en) * | 2017-08-01 | 2019-02-07 | Julius-Maximilians-Universitat Wurzburg | Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| RU2020116579A (ru) | 2017-10-25 | 2021-11-25 | Новартис Аг | Способы получения клеток, экспрессирующих химерный антигенный рецептор |
| WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
| JP7399880B2 (ja) * | 2018-01-26 | 2023-12-18 | ジェンザイム・コーポレーション | ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体 |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| EP3802825A1 (en) | 2018-06-08 | 2021-04-14 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| EP3623383A1 (en) | 2018-09-11 | 2020-03-18 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Improved bispecific flt3xcd3 antigen binding proteins |
| AU2019337394A1 (en) * | 2018-09-11 | 2021-03-25 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved anti-FLT3 antigen binding proteins |
| CR20210327A (es) * | 2018-12-18 | 2021-09-27 | Boehringer Ingelheim Io Canada Inc | Anticuerpos agonistas de flt3 y usos de estos |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
| EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| EP3962527A4 (en) | 2019-04-30 | 2023-11-01 | Senti Biosciences, Inc. | CHIMERIC RECEPTORS AND THEIR METHODS OF USE |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| BR112022016550A2 (pt) * | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
| JP7525109B2 (ja) | 2020-03-18 | 2024-07-30 | 学校法人金沢医科大学 | Ｃｄ１３５＋細胞を含む医薬組成物 |
| AU2021288224A1 (en) | 2020-06-11 | 2023-01-05 | Novartis Ag | ZBTB32 inhibitors and uses thereof |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022104061A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN118056008A (zh) | 2021-04-27 | 2024-05-17 | 诺华股份有限公司 | 病毒载体生产系统 |
| KR20240057457A (ko) * | 2021-08-16 | 2024-05-02 | 헤모제닉스 파마슈티컬스 엘엘씨 | 항-flt3 항체, car, car t 세포 및 사용 방법 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US572374A (en) | 1896-12-01 | Rod-cutting apparatus | ||
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5681566A (en) | 1988-10-24 | 1997-10-28 | 3I Research Exploitation Limited | Antibody conjugates with two or more covalently linked FC regions |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| CA2163345A1 (en) * | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| DE19608769C1 (de) | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DE19727814C1 (de) | 1997-06-30 | 1998-10-01 | Univ Eberhard Karls | Anitkörper 4G8B4B12 |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6403312B1 (en) | 1998-10-16 | 2002-06-11 | Xencor | Protein design automatic for protein libraries |
| US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
| US20020048772A1 (en) | 2000-02-10 | 2002-04-25 | Dahiyat Bassil I. | Protein design automation for protein libraries |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DE19958134C2 (de) | 1999-12-02 | 2003-05-15 | Koenig & Bauer Ag | Saugwalze |
| EP1330766A2 (en) | 2000-07-10 | 2003-07-30 | Xencor | Method for designing protein libraries with altered immunogenicity |
| US20030013951A1 (en) | 2000-09-21 | 2003-01-16 | Dan Stefanescu | Database organization and searching |
| ATE489395T1 (de) | 2000-12-12 | 2010-12-15 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| AU2002303929B9 (en) | 2001-05-31 | 2007-01-25 | E. R. Squibb & Sons, L.L.C. | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| EP1432980A4 (en) | 2001-08-10 | 2006-04-12 | Xencor Inc | AUTOMATED PROTEIN CONSTRUCTION FOR PROTEIN LIBRARIES |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US20080260731A1 (en) | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| KR20040008359A (ko) | 2002-07-18 | 2004-01-31 | 삼성전자주식회사 | 계층적 움직임 벡터 탐색을 이용한 움직임 추정 방법 및장치 및 그를 적용한 동영상 부호화 시스템 |
| EP3502133A1 (en) * | 2002-09-27 | 2019-06-26 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| EP1581904A2 (en) | 2003-01-08 | 2005-10-05 | Xencor, Inc. | Novel proteins with altered immunogenicity |
| WO2005018005A1 (en) | 2003-06-26 | 2005-02-24 | Rj Mears, Llc | Semiconductor device including mosfet having band-engineered superlattice |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF |
| US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US20060148009A1 (en) | 2004-10-12 | 2006-07-06 | Xencor, Inc. | Prediction and assessment of immunogenicity |
| JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するＦｃ変異体 |
| CA2624189A1 (en) * | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| EP2011870A4 (en) | 2006-04-14 | 2010-09-15 | Medical & Biol Lab Co Ltd | MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION |
| WO2008137382A1 (en) * | 2007-04-30 | 2008-11-13 | Centocor, Inc. | Anti-tissue factor antibodies and compositions with enhanced effector function |
| PE20140196A1 (es) * | 2007-08-09 | 2014-03-19 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| US9679104B2 (en) | 2013-01-17 | 2017-06-13 | Edico Genome, Corp. | Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform |
| US9703321B2 (en) | 2013-07-09 | 2017-07-11 | I-Blades, Inc. | Snap on wearable module |
-
2010
- 2010-12-23 JP JP2012545347A patent/JP5944831B2/ja active Active
- 2010-12-23 CA CA2785178A patent/CA2785178C/en active Active
- 2010-12-23 EP EP10798340.5A patent/EP2516468B1/en active Active
- 2010-12-23 HU HUE10798340A patent/HUE028629T2/en unknown
- 2010-12-23 EA EA201290370A patent/EA027502B1/ru unknown
- 2010-12-23 CN CN201080064659.3A patent/CN102770453B/zh active Active
- 2010-12-23 DK DK10798340.5T patent/DK2516468T3/da active
- 2010-12-23 BR BR112012015740-0A patent/BR112012015740B1/pt active IP Right Grant
- 2010-12-23 ES ES10798340.5T patent/ES2573642T3/es active Active
- 2010-12-23 WO PCT/EP2010/070659 patent/WO2011076922A1/en active Application Filing
- 2010-12-23 US US13/518,779 patent/US9023996B2/en active Active
- 2010-12-23 SI SI201031176A patent/SI2516468T1/sl unknown
-
2013
- 2013-01-02 HK HK13100006.7A patent/HK1172910A1/zh unknown
-
2016
- 2016-04-20 HR HRP20160422TT patent/HRP20160422T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012015740B1 (pt) | 2020-09-29 |
| US20120328612A1 (en) | 2012-12-27 |
| EP2516468A1 (en) | 2012-10-31 |
| ES2573642T3 (es) | 2016-06-09 |
| JP5944831B2 (ja) | 2016-07-05 |
| HRP20160422T1 (hr) | 2016-05-20 |
| EA027502B1 (ru) | 2017-08-31 |
| CN102770453A (zh) | 2012-11-07 |
| CA2785178A1 (en) | 2011-06-30 |
| WO2011076922A1 (en) | 2011-06-30 |
| HUE028629T2 (en) | 2016-12-28 |
| JP2013515472A (ja) | 2013-05-09 |
| CN102770453B (zh) | 2014-10-08 |
| CA2785178C (en) | 2019-09-03 |
| EP2516468B1 (en) | 2016-03-02 |
| US9023996B2 (en) | 2015-05-05 |
| EA201290370A1 (ru) | 2013-04-30 |
| HK1172910A1 (zh) | 2013-05-03 |
| SI2516468T1 (sl) | 2016-06-30 |
| BR112012015740A2 (pt) | 2017-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2516468T3 (da) | Anti-flt3-antistoffer og fremgangsmåder til anvendelse af disse | |
| KR102692379B1 (ko) | Pd-1과 특이적으로 결합하는 항체 및 사용 방법 | |
| CN110382536B (zh) | 抗pd-1抗体及其用途 | |
| AU2013262593B2 (en) | ST2 antigen binding proteins | |
| US7557190B2 (en) | Optimized proteins that target Ep-CAM | |
| US20220372154A1 (en) | Anti-tnfr2 antibodies and methods of use | |
| TW202216757A (zh) | 中和性抗ｓａｒｓ－ｃｏｖ－２抗體及其使用方法 | |
| KR20180054837A (ko) | 인간 cd40에 특이적으로 결합하는 작용성 항체 및 사용 방법 | |
| KR20180099723A (ko) | 항-tl1a/항-tnf-알파 이중특이적 항원 결합 단백질 및 그의 용도 | |
| KR20220040483A (ko) | 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도 | |
| TW201134488A (en) | PD-1 antibodies | |
| KR20070107687A (ko) | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 | |
| KR101817265B1 (ko) | 혈청 아밀로이드 ｐ 성분에 특이적인 항원 결합 단백질 | |
| KR20100057021A (ko) | 신규한 항체 | |
| KR20230017841A (ko) | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 | |
| KR20230041819A (ko) | Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도 | |
| KR20210076918A (ko) | 4-1bb 및 종양-관련 항원에 결합하는 항체 작제물 및 이의 용도 | |
| KR20160010391A (ko) | Cd20 및 cd95에 결합하는 재조합 이중특이성 항체 | |
| EP4214240B1 (en) | Anti-ccr8 antibodies | |
| KR20090114449A (ko) | Ｉｇｆ-ⅰｒ에 대한 항체 | |
| CN117545779A (zh) | 抗ctla-4抗体的用途 | |
| TW202229340A (zh) | 多特異性抗體及抗體組合 | |
| CN114174536A (zh) | 抗trem-1抗体及其用途 | |
| US20240103010A1 (en) | Pvrl2 and/or pvrig as biomarkers for treatment | |
| RU2823245C2 (ru) | Антитела, нацеливающиеся на C5aR |